CD133+ Stem Cells as Biomarkers in Duchenne Muscular Dystrophy
Author Information
Author(s): Marchesi Chiara, Belicchi Marzia, Meregalli Mirella, Farini Andrea, Cattaneo Alessandra, Parolini Daniele, Gavina Manuela, Porretti Laura, D'Angelo Maria Grazia, Bresolin Nereo, Cossu Giulio, Torrente Yvan
Primary Institution: Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Maggiore Policlinico, University of Milan
Hypothesis
Can the levels of circulating CD133+ stem cells predict the progression of Duchenne muscular dystrophy (DMD)?
Conclusion
The levels of CD133+CXCR4+CD34- cells could serve as a new prognostic clinical marker for the progression of DMD.
Supporting Evidence
- CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls.
- Levels of CD133+CXCR4+CD34- cells correlated with clinical condition and muscle strength.
- Patients with higher levels of CD133+CXCR4+CD34- cells exhibited slower disease progression.
Takeaway
This study found that certain stem cells in the blood can help doctors understand how Duchenne muscular dystrophy is progressing in patients.
Methodology
The study measured levels of CD133+ stem cells in blood samples from DMD patients and healthy controls using flow cytometry.
Potential Biases
Potential bias due to the small sample size and the exclusion of patients on steroid therapy.
Limitations
The study only included patients not on steroid therapy, which may limit the generalizability of the findings.
Participant Demographics
70 DMD patients aged 3 to 25 years, with a median age of 10.66 years.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website